Vetoquinol SA (EPA:VETO)

Market Cap	959.62M
Revenue (ttm)	539.20M
Net Income (ttm)	58.70M
Shares Out	11.83M
EPS (ttm)	n/a
PE Ratio	16.35
Forward PE	15.59
Dividend	0.89 (1.10%)
Ex-Dividend Date	Jun 4, 2024

Volume	1,468
Average Volume	9,361
Open	81.50
Previous Close	81.10
Day's Range	81.10 - 81.80
52-Week Range	63.60 - 106.00
Beta	1.07
RSI	64.20
Earnings Date	Mar 20, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,440
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.70 million, an increase of 5.65%.